- Piramal Pharma Solutions reports that, for the first time, revenue from innovation programmes has exceeded that from generic projects.
- The company’s innovation revenue has risen from 35% of total revenue in FY19 to over 50% in FY24, reflecting a compound annual growth rate (CAGR) of 20%.
Piramal Pharma Solutions, a Contract Development and Manufacturing Organization (CDMO) and a division of Piramal Pharma Ltd., has announced a significant shift in its revenue dynamics. For the first time in its history, the company’s revenue from innovation programmes has surpassed that of generic projects.
This milestone marks a notable change in Piramal Pharma Solutions’ business strategy and performance. Over the past five years, the proportion of revenue generated from innovation has increased from 35% to over 50%. This growth, representing a CAGR of 20%, reflects the company’s successful expansion in supporting pharma innovators across all stages of drug development.
Peter DeYoung, CEO of Piramal Pharma Solutions, commented, “Achieving this threshold is a significant milestone in the history of Piramal Pharma Solutions. For many years, our organizational strategies and tactics have focused on building the expertise and capabilities required to fully support innovator work. This breakthrough validates our efforts and secures our position as an innovator CDMO that supports customers in their quest to bring new, patient-centric medicines to regulated markets around the world.”
Piramal Pharma Solutions has successfully delivered over 125 integrated programmes, demonstrating its capability in providing comprehensive services from discovery through to commercial manufacturing. This includes high potency active pharmaceutical ingredients (HPAPIs), antibody-drug conjugations, peptide APIs, and sterile fill/finish services. The growth in innovation revenue underscores the company’s focus on high-value services and integrated solutions that reduce time-to-market and streamline operations.
Overview of outsourcing trends 
